Company News
Date Title
April 09th, 2025 Sirius Therapeutics announces U.S. FDA Clearance of IND to Begin Clinical Trial of Novel siRNA Therapy for Hyperlipoproteinemia(a)
March 20th, 2025 Sirius Therapeutics announces NMPA Approval to Begin Phase 1 Clinical Trial in China of NovelsiRNA Therapy for Hyperlipoproteinemia(a)
March 12th, 2025 Sirius Therapeutics Announces EMA Submission to Initiate a Phase 2 Clinical Trial of SRSD107, a Long–Acting, Next-Generation Anticoagulant for Thromboembolic Disorders
December 31st, 2024 Sirius Therapeutics Submits IND Application to NMPA for Another Novel siRNA Therapy
December 10th, 2024 Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders
December 03rd, 2024 Sirius Therapeutics to Present Data from Its Phase 1 Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders at the 66th ASH Annual Meeting and Exposition
July 11th, 2024 Sirius Therapeutics Completes Enrollment in Phase 1 Trial of SRSD107, a First-in-Class siRNA Being Developed for Anticoagulant
July 09th, 2024 Sirius Therapeutics Appoints Patrick Yue, MD, as Chief Medical Officer
April 01st, 2024 Sirius Therapeutics Announces Dosing of First Subject in Chinese Phase 1 Clinical Trial of FXI siRNA Anticoagulant
March 22nd, 2024 Sirius Completes Enrollment in Phase 1 Trial of a PCSK9 siRNA
March 05th, 2024 Sirius Therapeutics Announces China NMPA Approval for Human Clinical Trial of SRSD107, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders
February 02nd, 2024 Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders
January 25th, 2024 Emerging Company Profile: Chinese siRNA Specialist Sirius All In On Cardiovascular Disease
November 15th, 2023 Sirius Therapeutics Announces China NMPA Approval for Human Clinical Trial of SRSD101, a siRNA Therapeutic for Dyslipidemia
November 10th, 2023 Sirius Therapeutics Announces Submission to Begin First Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders
October 09th, 2023 Sirius Therapeutics Raised Nearly US$100 Million to Accelerate Clinical Development of siRNA Therapeutics
August 07th, 2022 Sirius Therapeutics appoints Dr. Qunsheng Ji CEO and to the Board of Directors
FOR MEDIA INQUIRIES, PLEASE CONTACT:

info@siriusrna.com

858-358-0096

Sirius Therapeutics, Inc., all rights reserved

Privacy Policy|Contact Us

为了更好的呈现效果，移动端请竖屏浏览